Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.

The USA's Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative ...

Data about two brain-penetrant BTK inhibitors for MS -- fenebrutinib and tolebrutinib -- were presented at the 2025 American Academy of Neurology (AAN) annual meeting.

Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a ...

ALAIN JOCARD/AFP via Getty Images Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases.

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Sanofi SAN-0.13%decrease; red down pointing triangle agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability ...

French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company (VNVC), which ...